Frontiers in Cardiovascular Medicine

FEBRUARY 17, 2025

IntroductionSince TAVR was approved for lower-risk aortic stenosis (AS) patients, managing post-implantation conduction disturbances has become crucial, especially with self-expanding heart valves (SEV).

Pacemaker 52

Pacemaker Aortic Stenosis Aortic valve 52

DAIC

MARCH 12, 2024

milla1cf Tue, 03/12/2024 - 16:48 March 12, 2024 — Medtronic plc , a global leader in healthcare technology, today announced two late-breaking data presentations on four-year outcomes from the Evolut Low Risk Trial. The findings showed a strong economic benefit of Evolut TAVR for low-risk patients from a U.S.

TAVR 52

TAVR Aortic valve Aortic Stenosis 52

Circulation: Cardiovascular Interventions

MARCH 26, 2025

Transcarotid transcatheter aortic valve replacement (TC-TAVR) has emerged as an alternative access in suboptimal transfemoral candidates, but no data exist comparing TC-TAVR and SAVR. At 30 days, the SAVR group showed a higher rate of the primary composite outcome compared with the TC-TAVR group (12.6%

Aortic valve 40

Aortic valve Aortic Stenosis TAVR 40

Open Heart

JANUARY 19, 2023

Objective Postprocedural ischaemic and bleeding risks after transcatheter aortic valve replacement (TAVR) remain a major concern. We aimed to assess the accuracy of percutaneous coronary intervention (PCI)-derived models and the performance of a recalibrated model that included variables more applicable to TAVR.

Aortic valve 52

Aortic valve TAVR Aortic Myocardial Infarction 52

DAIC

MARCH 21, 2024

Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for cardiologists, hands-down. The best possible outcome of this situation is inefficient workflow, driving higher overall cost of care and resulting in widespread physician and patient frustration. Why is that?

Pediatrics 86

Pediatrics Outcomes Patient Care Anatomy 86

Dr. S. Venkatesan MD

FEBRUARY 9, 2024

Reviewing NOTION study, the Nordic TAVI 10 year follow up has just been released (Ref 1) : Caution : Non-academic content This study reports the long-term outcome in low-risk individuals who required AVR. Now, some academic queries ? Was the outcome assessment blinded ? Was CAD accounted for outcome difference ?

Aortic valve 52

Aortic valve Aortic Academic Physiology 52

Cardiology Update

APRIL 9, 2024

The percent change from baseline in fasting triglycerides (TG) at six months served as the primary outcome measure. The percent change from baseline in fasting TG at six months served as the primary outcome measure. A total of 716 patients underwent TAVR with either a self-expanding supraannular valve or a balloon-expandable valve.

Angina 52

Angina Myocardial Infarction Aortic valve Coronary Artery Disease 52